source
- Trump executive order accelerates psychedelic drug development with priority review vouchers, funding and expanded right-to-tryPresident Trump signed an executive order that aims to speed the development and approval of psychedelic medicines. The order directs the FDA to issue priority review vouchers, expands right-to-tr…
- Avalo's Phase 2 data lifts shares 45% as skin drug shows 42% response in hidradenitis suppurativaAvalo Therapeutics reported that its experimental therapy abdakibart met the primary goal of a Phase 2 trial in patients with hidradenitis suppurativa. Both low and high dose groups achieved respon…BioPharma Dive · 4mo agoPositive readoutPositive